Legend Biotech : CARVYKTI™ (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, Receives U.S. FDA Approval for the Treatment of Adult Patients With Relapsed or Refractory Multiple Myeloma - Form 6-K

Press/Media

Period1 Mar 2022

Media coverage

1

Media coverage